SomnoMed Posts Record Half-Year Revenue and 35% EBITDA Lift, But FY26 Verdict Is Still to Come

Aditi Sarkar

27 July 2026 08:15 PM AEST

SomnoMed Posts Record Half-Year Revenue and 35% EBITDA Lift, But FY26 Verdict Is Still to Come

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

SomnoMed reported record half-year revenue of AUD 60.7 million and EBITDA of AUD 7.8 million, up 35%, on 27 February 2026; no FY26 full-year result had been lodged by 27 July 2026.

FY26 guidance was reaffirmed at AUD 119 million to AUD 126 million of revenue and AUD 10 million to AUD 12 million of EBITDA, with spending weighted to the second half.

Rest Assure was never discontinued, but its efficacy-monitoring clearance and commercial launch have slipped repeatedly since the October 2024 FDA decision.

Share-price attention may centre on whether SomnoMed delivers the operational and strategic milestones described in the update.

SomnoMed Limited did report record revenue and a 35% lift in EBITDA, but for the six months to 31 December 2025, not the full 2026 year. With FY26 results still weeks away, the sleep-apnoea device maker's reaffirmed guidance, repaired balance sheet and delayed Rest Assure launch are the real story.

The latest financial or clinical position

What was actually announced, and when On 27 February 2026, SomnoMed Limited (ASX:SOM) released results for the six months to 31 December 2025. Revenue was a record AUD 60.7 million, up 13% on the AUD 53.7 million a year earlier, or 8% in constant currency, stripping out exchange-rate movements.

That is a half-year record, and the company described it as such. It is not a full-year FY26 number. SomnoMed's 2026 financial year closed on 30 June 2026 and, as at 27 July 2026, no full-year result had been lodged with the ASX; announcements since February have been administrative only. FY25 results landed on 28 August 2025, so a late-August lodgement is a reasonable expectation, not a confirmed date.

Products, programmes and commercial context

For readers new to the stock, SomnoMed makes the SomnoDent mandibular advancement splint, a custom-fitted dental device that holds the lower jaw slightly forward to keep the airway open during sleep. Listed since 2004, it sells through dentists and sleep physicians across Europe, North America and Asia-Pacific.

Reading the EBITDA number properly EBITDA means earnings before interest, tax, depreciation and amortisation: trading profitability before financing and accounting charges. It is not profit, and it is not cash.

The next evidence and execution test

SomnoMed's AUD 7.8 million EBITDA, up 35% from AUD 5.8 million, is a company-defined figure, and the definition is doing real work. It excludes lease payments of AUD 1.6 million, share and option expenses of AUD 1.5 million, an unrealised foreign exchange movement of AUD 0.5 million and AUD 0.6 million of one-off restructuring costs. Underlying EBITDA after lease costs was AUD 6.2 million, up 42%, with EBITDA margin rising from 11% to 13%.

About SomnoMed

What Investors May Watch Next

Delivery against reported guidance and milestones

Product adoption or clinical programme progress

Cash use, funding and commercial investment

Regulatory developments and the SOM share-price response

Risks

The company faces clinical, regulatory, commercialisation, reimbursement, competition, funding and execution risks. Guidance and development timelines are forward-looking and may change. The supplied information is a point-in-time summary and does not establish future operational or share-price performance.

FAQs

Q: What is the latest development at SomnoMed?

A:SomnoMed Limited did report record revenue and a 35% lift in EBITDA, but for the six months to 31 December 2025, not the full 2026 year. With FY26 results still weeks away, the sleep-apnoea device maker's reaffirmed guidance, repaired balance sheet and delayed Rest Assure launch are the real story.

Q: What is a key figure from the update?

A:SomnoMed reported record half-year revenue of AUD 60.7 million and EBITDA of AUD 7.8 million, up 35%, on 27 February 2026; no FY26 full-year result had been lodged by 27 July 2026.

Q: What is the next milestone for SomnoMed?

A:Rest Assure was never discontinued, but its efficacy-monitoring clearance and commercial launch have slipped repeatedly since the October 2024 FDA decision.

Q: What may influence the SOM share price?

A:Operational delivery, funding, reported milestones, sector conditions and the risks described in the article may influence the SOM share price.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.